The ALK-rearranged CRC patient identified as part of the NEXT-1 trial harbors the EML4-ALK (E21:A20) where exons 1–21 of EML4 is fused to exons 20–29 of ALK which has been reported only once in CRC [5] but so far has not been reported in ALK-rearranged NSCLC. This evidence concerns the gene EML4 and non-small cell lung carcinoma.